New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial
NCT ID NCT06671379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study compares a new experimental drug, SHR-A2009, to standard chemotherapy in 498 people with advanced EGFR-mutated non-small cell lung cancer whose current targeted therapy (EGFR TKI) has stopped working. The goal is to see if SHR-A2009 can better control the cancer and extend life. Participants receive either SHR-A2009 or a chemo combination (pemetrexed plus carboplatin or cisplatin) by IV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A2009 (an experimental drug given by IV)
What this could lead to
If it works, this could offer a new treatment option for people with EGFR-mutant lung cancer whose current targeted therapy has stopped working.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than chemo, and side effects are unknown. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China